Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer

David N. Danforth, Jo Anne Zujewski, Joyce O'Shaughnessy, David Riseberg, Seth M. Steinberg, Nanette McAtee, Marianne Noone, Catherine Chow, Usha Chaudhry, Marc Lippman, Joan Jacobson, Paul Okunieff, Kenneth H. Cowan

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Stage IIIA,B breast cancer is commonly treated with neoadjuvant chemotherapy because of high objective response rates and improved operability. Criteria for subsequent selection of local therapy- mastectomy, radiotherapy, or both-are not well defined. We adopted a policy of selective local therapy based on rebiopsy of the breast and clinical axillary lymph node status at the time of best response to chemotherapy. Methods: Between 1980 and 1993, 126 patients with stage IIIA,B breast cancer were treated with neoadjuvant chemotherapy and definitive local therapy. The long-term incidence of locoregional failure (in-breast, chest wall, axilla, supraclavicular, neck), relapse-free survival, and overall survival was determined. ReSults: The overall clinical objective response rate to chemotherapy was 95.2%. Eighty-three patients underwent mastectomy, with negative margins achieved in 91.6%. Forty-two patients had breast preservation; the overall in-breast recurrence rate was 19.0% (8 of 42 patients). The overall locoregional recurrence rate by site was: chest wall- 8.7% (11 of 126 patients), axilla-8.7% (11 of 126 patients), supraclavicular- 5.6% (7 of 126 patients), and neck-4.0% (5 of 126 patients). The axillary recurrence rate was 6.6% (5 of 76 patients) for clinically negative axilla treated with radiotherapy only, and 12.0% (6 of 50 patients) for clinically positive axilla treated with surgery only. The overall long-term survival probabilities (6 years) according to stage were: stage IIIA-58.0%, stage IIIB(noninflam)-58.0%, stage IIIB(inflam)-36.0%. Conclusions: These findings support a selective approach to local therapy in patients with stage IIIA,B breast cancer. This approach provides local control in most patients, and allows for breast preservation and elimination of axillary dissection in selected patients.

Original languageEnglish (US)
Pages (from-to)150-158
Number of pages9
JournalAnnals of Surgical Oncology
Volume5
Issue number2
DOIs
StatePublished - Mar 1 1998

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Drug Therapy
Axilla
Breast
Recurrence
Mastectomy
Thoracic Wall
Survival
Neck
Radiotherapy
Therapeutics
Patient Selection
Dissection

Keywords

  • Breast radiotherapy
  • Inflammatory breast cancer
  • Mastectomy
  • Neoadjuvant chemotherapy
  • Stage III breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Danforth, D. N., Zujewski, J. A., O'Shaughnessy, J., Riseberg, D., Steinberg, S. M., McAtee, N., ... Cowan, K. H. (1998). Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Annals of Surgical Oncology, 5(2), 150-158. https://doi.org/10.1007/BF02303848

Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. / Danforth, David N.; Zujewski, Jo Anne; O'Shaughnessy, Joyce; Riseberg, David; Steinberg, Seth M.; McAtee, Nanette; Noone, Marianne; Chow, Catherine; Chaudhry, Usha; Lippman, Marc; Jacobson, Joan; Okunieff, Paul; Cowan, Kenneth H.

In: Annals of Surgical Oncology, Vol. 5, No. 2, 01.03.1998, p. 150-158.

Research output: Contribution to journalArticle

Danforth, DN, Zujewski, JA, O'Shaughnessy, J, Riseberg, D, Steinberg, SM, McAtee, N, Noone, M, Chow, C, Chaudhry, U, Lippman, M, Jacobson, J, Okunieff, P & Cowan, KH 1998, 'Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer', Annals of Surgical Oncology, vol. 5, no. 2, pp. 150-158. https://doi.org/10.1007/BF02303848
Danforth DN, Zujewski JA, O'Shaughnessy J, Riseberg D, Steinberg SM, McAtee N et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Annals of Surgical Oncology. 1998 Mar 1;5(2):150-158. https://doi.org/10.1007/BF02303848
Danforth, David N. ; Zujewski, Jo Anne ; O'Shaughnessy, Joyce ; Riseberg, David ; Steinberg, Seth M. ; McAtee, Nanette ; Noone, Marianne ; Chow, Catherine ; Chaudhry, Usha ; Lippman, Marc ; Jacobson, Joan ; Okunieff, Paul ; Cowan, Kenneth H. / Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. In: Annals of Surgical Oncology. 1998 ; Vol. 5, No. 2. pp. 150-158.
@article{70860f02a88d45919a52b56ee36ad164,
title = "Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer",
abstract = "Background: Stage IIIA,B breast cancer is commonly treated with neoadjuvant chemotherapy because of high objective response rates and improved operability. Criteria for subsequent selection of local therapy- mastectomy, radiotherapy, or both-are not well defined. We adopted a policy of selective local therapy based on rebiopsy of the breast and clinical axillary lymph node status at the time of best response to chemotherapy. Methods: Between 1980 and 1993, 126 patients with stage IIIA,B breast cancer were treated with neoadjuvant chemotherapy and definitive local therapy. The long-term incidence of locoregional failure (in-breast, chest wall, axilla, supraclavicular, neck), relapse-free survival, and overall survival was determined. ReSults: The overall clinical objective response rate to chemotherapy was 95.2{\%}. Eighty-three patients underwent mastectomy, with negative margins achieved in 91.6{\%}. Forty-two patients had breast preservation; the overall in-breast recurrence rate was 19.0{\%} (8 of 42 patients). The overall locoregional recurrence rate by site was: chest wall- 8.7{\%} (11 of 126 patients), axilla-8.7{\%} (11 of 126 patients), supraclavicular- 5.6{\%} (7 of 126 patients), and neck-4.0{\%} (5 of 126 patients). The axillary recurrence rate was 6.6{\%} (5 of 76 patients) for clinically negative axilla treated with radiotherapy only, and 12.0{\%} (6 of 50 patients) for clinically positive axilla treated with surgery only. The overall long-term survival probabilities (6 years) according to stage were: stage IIIA-58.0{\%}, stage IIIB(noninflam)-58.0{\%}, stage IIIB(inflam)-36.0{\%}. Conclusions: These findings support a selective approach to local therapy in patients with stage IIIA,B breast cancer. This approach provides local control in most patients, and allows for breast preservation and elimination of axillary dissection in selected patients.",
keywords = "Breast radiotherapy, Inflammatory breast cancer, Mastectomy, Neoadjuvant chemotherapy, Stage III breast cancer",
author = "Danforth, {David N.} and Zujewski, {Jo Anne} and Joyce O'Shaughnessy and David Riseberg and Steinberg, {Seth M.} and Nanette McAtee and Marianne Noone and Catherine Chow and Usha Chaudhry and Marc Lippman and Joan Jacobson and Paul Okunieff and Cowan, {Kenneth H.}",
year = "1998",
month = "3",
day = "1",
doi = "10.1007/BF02303848",
language = "English (US)",
volume = "5",
pages = "150--158",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer

AU - Danforth, David N.

AU - Zujewski, Jo Anne

AU - O'Shaughnessy, Joyce

AU - Riseberg, David

AU - Steinberg, Seth M.

AU - McAtee, Nanette

AU - Noone, Marianne

AU - Chow, Catherine

AU - Chaudhry, Usha

AU - Lippman, Marc

AU - Jacobson, Joan

AU - Okunieff, Paul

AU - Cowan, Kenneth H.

PY - 1998/3/1

Y1 - 1998/3/1

N2 - Background: Stage IIIA,B breast cancer is commonly treated with neoadjuvant chemotherapy because of high objective response rates and improved operability. Criteria for subsequent selection of local therapy- mastectomy, radiotherapy, or both-are not well defined. We adopted a policy of selective local therapy based on rebiopsy of the breast and clinical axillary lymph node status at the time of best response to chemotherapy. Methods: Between 1980 and 1993, 126 patients with stage IIIA,B breast cancer were treated with neoadjuvant chemotherapy and definitive local therapy. The long-term incidence of locoregional failure (in-breast, chest wall, axilla, supraclavicular, neck), relapse-free survival, and overall survival was determined. ReSults: The overall clinical objective response rate to chemotherapy was 95.2%. Eighty-three patients underwent mastectomy, with negative margins achieved in 91.6%. Forty-two patients had breast preservation; the overall in-breast recurrence rate was 19.0% (8 of 42 patients). The overall locoregional recurrence rate by site was: chest wall- 8.7% (11 of 126 patients), axilla-8.7% (11 of 126 patients), supraclavicular- 5.6% (7 of 126 patients), and neck-4.0% (5 of 126 patients). The axillary recurrence rate was 6.6% (5 of 76 patients) for clinically negative axilla treated with radiotherapy only, and 12.0% (6 of 50 patients) for clinically positive axilla treated with surgery only. The overall long-term survival probabilities (6 years) according to stage were: stage IIIA-58.0%, stage IIIB(noninflam)-58.0%, stage IIIB(inflam)-36.0%. Conclusions: These findings support a selective approach to local therapy in patients with stage IIIA,B breast cancer. This approach provides local control in most patients, and allows for breast preservation and elimination of axillary dissection in selected patients.

AB - Background: Stage IIIA,B breast cancer is commonly treated with neoadjuvant chemotherapy because of high objective response rates and improved operability. Criteria for subsequent selection of local therapy- mastectomy, radiotherapy, or both-are not well defined. We adopted a policy of selective local therapy based on rebiopsy of the breast and clinical axillary lymph node status at the time of best response to chemotherapy. Methods: Between 1980 and 1993, 126 patients with stage IIIA,B breast cancer were treated with neoadjuvant chemotherapy and definitive local therapy. The long-term incidence of locoregional failure (in-breast, chest wall, axilla, supraclavicular, neck), relapse-free survival, and overall survival was determined. ReSults: The overall clinical objective response rate to chemotherapy was 95.2%. Eighty-three patients underwent mastectomy, with negative margins achieved in 91.6%. Forty-two patients had breast preservation; the overall in-breast recurrence rate was 19.0% (8 of 42 patients). The overall locoregional recurrence rate by site was: chest wall- 8.7% (11 of 126 patients), axilla-8.7% (11 of 126 patients), supraclavicular- 5.6% (7 of 126 patients), and neck-4.0% (5 of 126 patients). The axillary recurrence rate was 6.6% (5 of 76 patients) for clinically negative axilla treated with radiotherapy only, and 12.0% (6 of 50 patients) for clinically positive axilla treated with surgery only. The overall long-term survival probabilities (6 years) according to stage were: stage IIIA-58.0%, stage IIIB(noninflam)-58.0%, stage IIIB(inflam)-36.0%. Conclusions: These findings support a selective approach to local therapy in patients with stage IIIA,B breast cancer. This approach provides local control in most patients, and allows for breast preservation and elimination of axillary dissection in selected patients.

KW - Breast radiotherapy

KW - Inflammatory breast cancer

KW - Mastectomy

KW - Neoadjuvant chemotherapy

KW - Stage III breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0344528645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344528645&partnerID=8YFLogxK

U2 - 10.1007/BF02303848

DO - 10.1007/BF02303848

M3 - Article

C2 - 9527268

AN - SCOPUS:0344528645

VL - 5

SP - 150

EP - 158

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -